Core Viewpoint - Karolinska Development AB's portfolio company, Modus Therapeutics, has initiated the second part of a phase 2a clinical study for sevuparin, targeting chronic kidney disease with anemia, following a successful first part that demonstrated safety and provided insights for dose selection [1][2][4]. Group 1: Clinical Study Details - The second part of the phase 2a study will focus on repeated dosing of sevuparin, assessing safety and clinically relevant efficacy outcomes, including hemoglobin and hepcidin levels, along with other kidney- and blood-related biomarkers [3]. - A total of 50 to 60 patients will be enrolled in this study [3]. Group 2: Company Background and Ownership - Karolinska Development holds a 54% direct and 1% indirect ownership stake in Modus Therapeutics [4]. - The company is a Nordic life sciences investment firm that seeks to identify and develop breakthrough medical innovations, aiming to create and grow companies that can deliver impactful medical products [5][6]. Group 3: Strategic Focus - Karolinska Development collaborates with leading universities and research institutes in the Nordic region to access world-class medical innovations, focusing on building companies around top scientists supported by experienced management teams [6]. - The company has a portfolio of eleven companies that target innovative treatments for serious diseases, led by a team of investment professionals with a strong track record [7].

Core Viewpoint - Umecrine Cognition has successfully raised SEK 24.6 million through a convertible loan to support its ongoing clinical Phase 1b/2a study of golexanolone in primary biliary cholangitis, with participation from existing shareholders including Karolinska Development [1][3]. Group 1: Clinical Study Details - Umecrine Cognition is conducting the second part of its clinical Phase 1b/2a study, aiming to recruit 84 patients across over 30 sites in eight countries [2]. - The first part of the study concluded with interim results indicating that golexanolone was well-tolerated, safe, and resulted in only mild adverse events, achieving clinically relevant drug exposure levels and positive outcomes in anxiety and depression scoring [2]. Group 2: Funding and Ownership - The convertible loan, which includes attached share options, is directed to a consortium of investors, including Karolinska Development, AB Ility, and Ribbskottet AB, and will finance the clinical trial and operational expenses [3]. - Karolinska Development currently holds a 73% ownership stake in Umecrine Cognition, which will decrease to 62% upon conversion of the loan and full exercise of the share options [4]. Group 3: Company Background - Karolinska Development is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the region [5][6]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases and is supported by a team of experienced investment professionals [7].